MOTS-c, a signaling protein made from genes in the cell’s energy-producing parts, is sold as an injectable product to adults seeking exercise-like effects on blood sugar, body fat and physical capacity. It remains a promising laboratory finding: no study comparing MOTS-c itself with a placebo has reported results, and safety is largely unknown. It is banned in tested sport; United States pharmacy access remains unsettled. (Full Review)

Protocol

Gray-market community protocol

5–10 mg three times weekly or 1–2 mg daily

Subcutaneous; user practice, not trial-validated; no validated human dose of native MOTS-c exists

Analog trial regimen

CB4211 25 mg once daily, four weeks

Subcutaneous; an analog, not dose-equivalent to MOTS-c

Time of day

Morning or pre-exercise

Common practice; no human data

Time to effect

Liver enzymes (analog)

Four weeks

Lower ALT and AST with CB4211

Blood glucose (analog)

Four weeks

Lower glucose with CB4211

Metabolic effects (mice)

1–2 weeks

Human time to effect for native MOTS-c is unknown

Benefits

Low: Blood glucose control and insulin sensitivity, liver enzyme reduction in fatty liver disease, muscle function and age-related physical decline, body fat reduction, lifespan extension, blood vessel and heart health

Speculative: Bone loss prevention, pancreatic islet protection

Contraindications

Athletes subject to anti-doping testing

People with a history of allergic reactions to peptide drugs (no human data)

Pregnant or breastfeeding women (no human data)

Children and adolescents (no human data)

People with diabetes using insulin or sulfonylureas without glucose monitoring (no human data)

Key Interactions

Theoretical (inferred from mechanism)

Insulin and sulfonylureas (glipizide, glimepiride): additive glucose lowering; hypoglycemia

Other glucose-lowering drug classes: metformin and GLP-1 receptor agonists (semaglutide, tirzepatide); additive glucose lowering

Antifolate drugs (methotrexate, pemetrexed): effects could add; consequence unknown

AMPK-activating supplements (berberine, alpha-lipoic acid): additive glucose lowering

High-dose folic acid or folinic acid: could blunt MOTS-c effects

Exercise: combined effects on glucose could be additive

Risk & Side Effects

Low: Injection-site reactions

Speculative: Immune reactions and product impurities, low blood sugar with glucose-lowering drugs, increased inflammatory signals from aged cells

Monitoring

Marker	Target	Why
Fasting glucose	70–99 mg/dL	Glucose response; low-glucose safety check
Fasting insulin	About 2.6–24.9 µIU/mL	Insulin sensitivity
HbA1c	4.0–5.6%	Glucose change over months
ALT	About 7–55 U/L	Analog response; liver-injury safety check
AST	About 8–48 U/L	Analog response; liver-injury safety check
Body fat mass by DEXA	No established target; track change from own baseline	Fat-mass change

Cadence: Baseline panel before starting; fasting glucose and liver enzymes at 4 weeks, then every 3 months; HbA1c and body composition every 3–6 months; daily glucose checks during the first 1–2 weeks with insulin or sulfonylureas

Qualitative Assessment

Injection-site condition (redness, swelling, lumps)
Exercise tolerance and perceived endurance
Energy levels across the day
Signs of low blood sugar (shakiness, sweating, sudden hunger), especially with glucose-lowering drugs
Allergic symptoms (hives, itching, facial swelling)

MOTS-c for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment